Pioneering Precision Medicine: A New Model for CDx Development & Commercialization

Type: On-Demand Webinar
Location: Global
Areas of Interest: BioPharma, Liquid Biopsy

SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.

In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:

Discover SOPHiA GENETICS’ and Myriad Genetics’ first-of-its kind CDx partnership model to unlock scale, regulatory compliance, and access to precision diagnostics and therapies.
Gain insights into what a co-development strategy for CTA and CDx looks like in practice and how it enables simultaneous development and deployment at a central lab.
Understand how Pharma-Diagnostics collaborations can support late-stage clinical development through commercialization.

Topics:

The Hybrid CDx Model: A New Paradigm for Pharma Partnerships
The Business Structure Behind SOPHiA GENETICS and Myriad Genetics Alliance
Co-Developing a CTA-CDx: What Does it Look Like in Practice?
From Single-Site CDx to a Global Distributed Kit: Scaling with the SOPHiA GENETICS Vision
Going Beyond a Single Test: Expanding Myriad Genetics’ Portfolio
Panel Discussion: Is a Hybrid Model the Future?

Speakers:

Kristina McGuire – Executive Director & Head, Precision Medicine Laboratory Operations & Companion Diagnostics, Regeneron
Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA
Vern Geckler – Senior Director, Alliance Management, Myriad Genetics
Julien Pontis - Head of CDx & Clinical Diagnostics, SOPHiA GENETICS
Drew Gibbs – Vice President, Business Development, Myriad Genetics
Yves Serroen - Director, BioPharma Business Development, SOPHiA GENETICS
Janni Mirosevich – Senior Director, BioPharma Business Development, SOPHiA GENETICS
Dale Muzzey – Chief Scientific Officer, Myriad Genetics
Jonathan Beer – Senior Director, Precision Medicine, Bristol Myers Squibb
Brian Baker – Executive Director, Regulatory Affairs, In Vitro Diagnostics, Regeneron
Michael Senior – Senior Director, Diagnostic Partnerships, Oncology Business Unit, AstraZeneca

Watch Webinar

Email

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services